Helping you develop
biologics faster and easier
for patients in need

Deep knowledge of
pre-clinical technologies
and methods

Transparency throughout
development
 

Home 2018-06-13T02:40:55+00:00

Webinar: High-Throughput Developability Assessment of Therapeutic Antibody Candidates in Discovery Stage

Broadcast Date: Wednesday, June 20, 2018
Time: 8 am PT, 11 am ET, 17:00 CEST

Event Registraton

The stability of a candidate drug-protein is critical to the success or failure of its development as a viable drug. Low stability could adversely impact production consistency, shipping and handling excursions, and long-term storage. Developability assessments are becoming an increasingly important criterion to mitigate this risk. The conventional approach is to perform the developability assessment on the final few shortlisted candidates at the mid-to-late stage of drug development.

I usually take 2 Levitra tablets a week which is more than enough for me to forget about erectile dysfunction thanks to https://edmeans.com/. From one tablet the effect lasts several hours. Over time, it weakens, but all the same, an erection occurs with any stimulation.

At Aragen, we have moved the developability assessment into the discovery phase during antibody screening, accelerating the candidate selection process. Integration of the Uncle platform into our process was essential for early assessments due to its small sample requirements and rapid analysis time. In this study, we show that humanized antibody candidates of a murine monoclonal antibody differ in their thermal melting and thermal aggregation profiles due to differences in the stability of the Fab domain (that carries the target binding residues) because of the humanization process. Destabilization of the Fab domain or lower aggregation onset can lead to problems later during production, shipment, or storage. Assessment of thermal stability and aggregation potential can be an important tool for early selection of viable drug candidates. Analysis during antibody screening (discovery stage) and clone selection (early process development stage) can significantly reduce the time and cost of downstream manufacturing.

This presentation by Aragen Bioscience is sponsored by Unchained Labs and hosted by Genetic Engineering News. A live Q&A session will follow the presentations, offering you a chance to pose questions to our expert panelist.

Event Registraton

Upcoming Events

Cell Line Development & Engineering
San Francisco, CA
June 12-14

Aragen Webinar

Broadcast Date: June 20
Time: 8 am PT, 11 am ET, 17:00 CEST

View events

Press Releases

3.19.2018

Aragen Bioscience Expands RapTr Cell Line Development Services

11.10.2017
Aragen Bioscience Announces AAALAC Accreditation

06.20.2017
RapTr Cell Line Development Services Introduced